An Exploratory Study Comparing Two Nicotine Inhalers
6. Juli 2012 aktualisiert von: McNeil AB
A Proof of Concept With a New Nicotine Inhaler in Comparison With Nicotine Inhaler 10 mg
Subjects will be screened within 28 days before the first study treatment to confirm that they meet the requirements to participate in the trial.
They will return to the site for two treatment visits, at least 12 hours each, and at least one day in between visits.
At each visit treatment N1/3-I5 or Nicotine Inhaler 10 mg will be administered every hour for 11 hours.
The investigator (or an appropriate delegate at the investigator site) will obtain informed consent from each subject.
Blood samples will be drawn on a special schedule.
The total predicted amount of blood sampled from each subject is 174 mL over the whole study.
Subjects will be required to follow specific smoking and dietary restrictions and rate their urges to smoke, general liking of the product, and how easy the product is to use.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Blood for pharmacokinetic analyses will be drawn prior to the first administration and immediately before administration at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 hours. Thereafter samples will be drawn at 5, 10, 15, 20, 25, 30, 45, and 60 minutes after the 11-hour administration. Easiness of use will be rated using an 8-grade ordered category scale at 10 minutes after the start of administrations at 3, 6, and 9 hours. Overall liking will be rated using an 8-grade ordered category scale at 12 hours. Urges to smoke will be rated on a 4-grade ordered category scale immediately before and at 15 minutes after the first administration, and as well as before and 15 minutes after the start of administrations at 3, 6, and 9 hours, and at 12 hours. Used cartridges will be collected. Pooled samples per subject and treatment will be analyzed to determine the amount of remaining nicotine. Tolerability of the treatments will be evaluated in terms of reported and observed adverse events (AE).
Since the primary objective is to compare steady-state nicotine pharmacokinetics of N1/3-I5 with that of Nicotine Inhaler 10 mg, this study will have a multiple-dose setting. A crossover design has been chosen for this study in order to allow within-subject comparisons of treatments. Healthy habituated adults smoking at least 10 cigarettes daily for at least one year preceding inclusion will be included in the study, since they are expected to tolerate the doses of nicotine that will be administered.
Studientyp
Interventionell
Einschreibung (Tatsächlich)
36
Phase
- Frühphase 1
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Lund, Schweden, 222 20
- McNeil AB Clinical Pharmacology R&D
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
19 Jahre bis 50 Jahre (Erwachsene)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Healthy (per protocol-specified parameters) male or female subjects between the ages of 19 and 50 years, inclusive.
- Smoking of at least 10 cigarettes daily during at least one year preceding inclusion.
- For females: Postmenopausal state or premenopausal/perimenopausal state with a protocol-specified effective means of contraception or declared absence of sexual contact with a male partner during the study.
- For males: No pregnant spouse or partner at screening and willingness to protect potential spouse or partner from becoming pregnant during the study.
- Body Mass Index (BMI) within protocol-specified parameters.
- A personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
- Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures specified in the protocol
Exclusion Criteria:
- Evidence or history of an acute or chronic medical or psychiatric condition or allergy or laboratory abnormality, or of use of drugs that, in the judgment of the investigator or an authorized study physician, may increase the risk associated with study participation or interfere with the interpretability of study results.
- Females: Pregnancy, breast-feeding, premenopausal, or perimenopausal, state with insufficient contraception as specified under Inclusion Criteria.
- Males: Pregnant spouse or partner or no willingness to prevent conception in a spouse or partner.
- History of regular alcohol consumption outside the protocol-specified allowances.
- Treatment with an investigational drug within 3 months preceding the first dose of study treatment.
- Known sensitivity to heparin or history of heparin-induced thrombocytopenia.
- Pathological oral status interfering with normal muscular, sensory, or absorptive function of the oral cavity. Piercing of tongue and lips is considered to impair oral function.
- Relationship to persons involved directly with the conduct of the study, or their families.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: N1/3-I5
5 mg Inhalation during 10 minutes every hour for 11 hours with a puff frequency of four puffs per minute, with a 36-hour washout between visits
|
Nicotine 5 mg Inhaler
Andere Namen:
Nicotine 10 mg Inhaler
Andere Namen:
|
|
Aktiver Komparator: NX-I10
10 mg Inhalation during 10 minutes every hour for 11 hours with a puff frequency of four puffs per minute, with a 36-hour washout between visits.
|
Nicotine 5 mg Inhaler
Andere Namen:
Nicotine 10 mg Inhaler
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Maximum Observed Plasma Concentration (Cmax)
Zeitfenster: During last dosing interval 11-12 hours post-dose
|
Maximum Observed Plasma Concentration (Cmax), which is the maximum (peak) concentration (amount of drug) measurable in blood plasma after a dose is administered, measured in nanograms/milliliter (ng/mL)
|
During last dosing interval 11-12 hours post-dose
|
|
Average Concentration (Cav)
Zeitfenster: During last dosing interval 11-12 hours post-dose
|
The average concentration of nicotine in the blood. * The dosing interval (τ) in this study will be one (1) hour. Consequently, Cav will have the same value as AUCτ (but with a different unit), since Cav is calculated as AUCτ divided by τ. Therefore Cav will not be displayed in results, only AUCτ. |
During last dosing interval 11-12 hours post-dose
|
|
Bioavailability [AUCτ]
Zeitfenster: During last dosing interval 11-12 hours post-dose
|
AUCτ is the area under the plasma concentration-vs.-time
curve during the last dosing interval and is a measure of how much of the drug reaches the person's bloodstream.
The Area Under the Curve (AUC) is calculated by plotting the drug's blood levels on a graph at different times during the set period.
The area under this curve is calculated as hour * nanograms (ng) per milliliter (mL).
|
During last dosing interval 11-12 hours post-dose
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Minimum Observed Plasma Concentration (Cmin)
Zeitfenster: During last dosing interval 11-12 hours post-dose
|
Minimum Observed Plasma Concentration (Cmin), which is the minimum concentration (amount of drug) measurable in blood plasma after a dose is administered, measured in nanograms/milliliter (ng/mL)
|
During last dosing interval 11-12 hours post-dose
|
|
Time of Maximum Concentration (Tmax)
Zeitfenster: During last dosing interval 11-12 hours post-dose
|
The time at which maximum concentration is reached (Tmax)
|
During last dosing interval 11-12 hours post-dose
|
|
Peak Trough Fluctuation (PTF)
Zeitfenster: During last dosing interval 11-12 hours post-dose
|
Peak trough fluctuation within one dosing interval at steady state.
|
During last dosing interval 11-12 hours post-dose
|
|
Swing
Zeitfenster: During last dosing interval 11-12 hours post-dose
|
Swing within one dosing interval at steady state.
|
During last dosing interval 11-12 hours post-dose
|
|
Baseline-corrected Pre-Dosing Plasma Concentration (Cn)
Zeitfenster: 0 Minutes
|
Baseline-corrected nicotine plasma concentrations immediately before each user session (Cn)
|
0 Minutes
|
|
Residual Nicotine
Zeitfenster: 12 hours
|
Used cartridges will be collected.
Pooled samples per subject and treatment will be analyzed to determine the amount of remaining nicotine.
|
12 hours
|
|
Urges to Smoke
Zeitfenster: During 12 hours
|
Subjects will rate their urges to smoke on a category scale from 1 to 4, where 1= No or very light urge to smoke, and 4= Very strong or extreme urge to smoke.
|
During 12 hours
|
|
Overall Liking
Zeitfenster: at 12 hours
|
Overall Liking will be rated on a category scale from 1 to 8, where 1= extremely good and 8=extremely bad.
|
at 12 hours
|
|
Ease of Use
Zeitfenster: During 9 hours
|
Ease of use will be rated at specific categorical time points, on a scale of 1-8, where 1= extremely easy and 8=extremely hard..
|
During 9 hours
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. November 2011
Primärer Abschluss (Tatsächlich)
1. Dezember 2011
Studienabschluss (Tatsächlich)
1. Dezember 2011
Studienanmeldedaten
Zuerst eingereicht
21. November 2011
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
21. November 2011
Zuerst gepostet (Schätzen)
23. November 2011
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
10. Juli 2012
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
6. Juli 2012
Zuletzt verifiziert
1. Juli 2012
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Psychische Störungen
- Chemisch induzierte Störungen
- Substanzbezogene Störungen
- Tabakkonsumstörung
- Physiologische Wirkungen von Arzneimitteln
- Neurotransmitter-Agenten
- Molekulare Mechanismen der pharmakologischen Wirkung
- Autonome Agenten
- Agenten des peripheren Nervensystems
- Cholinerge Wirkstoffe
- Ganglionäre Stimulanzien
- Nikotin-Agonisten
- Cholinerge Agonisten
- Nikotin
Andere Studien-ID-Nummern
- NICTDP0002
- 2011-002796-41 (EudraCT-Nummer)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Nicotine
-
University of California, San FranciscoNational Institute on Drug Abuse (NIDA)RekrutierungNikotinabhängigkeit | Nikotin DampfenVereinigte Staaten